Skip to content

All Lessons

GDUFA III Impact on Drug Master File (DMF) Assessment

GDUFA III Redesigned Pre-Submission (PSUB) Meeting: Overview, Process, and What’s New?

General Quality Considerations of Drug Products Labeled for Alternate Dosing Administration

GIDWG Global IDMP Identifiers

Global IDMP Implementation: Getting Closer to the Goal

Global IDMP Implementation: Readiness

Global Market Innovation with Medical Device Export Certificates

Good Laboratory Practice (GLP)

HCT/P Donor Screening/Testing and Requests for Exemption (REdI 2024 – Biologics Track)

How to Leverage the Inactive Ingredient Database (IID) and Safety Justification

ICH M12 Drug Interaction Studies Final Guidance

Immediate-use Syringes and the Risks of Extended Use (FDA Compounding Conference 2025)

Impact of FDA’s International Arrangements on Pharmaceutical Products

Impact of ICH M13A Implementation on Bioequivalence Assessment: Removal of Data Due to Low Exposure

In Vitro DDI Assessments (ICH M12 Drug-Drug Interaction Studies)

Industry Perspectives on Particle Size Measurement

Informed Consent: More Than Just a Document

Innovations in Medical Device Remanufacturing and Servicing

Innovative Approaches to Clinical Trials

Innovative Approaches to Emerging Threats

Innovative Therapeutics: Gene Therapy (Clinical Investigator Training Course 2024)

Insights and Remarks from Keynote Speaker (Cell Therapies and Tissue-Based Products)

International Clinical Trials

International Instrument on Plastic Pollution

Introduction and Overview of the Model Master File  

1 … 6 7 8 9 10 … 16
Share: